Micronized 17B-estradiol

Phase 2/3Completed
1 views this week 0 watching💤 Quiet
Interest: 38/100
38
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Atherosclerosis

Conditions

Atherosclerosis, Postmenopause

Trial Timeline

Apr 1, 1994 → Nov 1, 1998

About Micronized 17B-estradiol

Micronized 17B-estradiol is a phase 2/3 stage product being developed by Johnson & Johnson for Atherosclerosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00115024. Target conditions include Atherosclerosis, Postmenopause.

What happened to similar drugs?

13 of 20 similar drugs in Atherosclerosis were approved

Approved (13) Terminated (3) Active (6)

Hype Score Breakdown

Clinical
15
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00115024Phase 2/3Completed

Competing Products

20 competing products in Atherosclerosis

See all competitors
ProductCompanyStageHype Score
Orforglipron + PlaceboEli LillyPhase 3
47
Olmesartan medoxomil + PlaceboDaiichi SankyoPhase 3
40
Pactimibe sulfateDaiichi SankyoPhase 2/3
30
PactimibeDaiichi SankyoPhase 2
35
Bempedoic acid + Ezetimibe + Rosuvastatin + AtorvastatinDaiichi SankyoPhase 3
47
Rosuvastatin + placebo + aspirin + placeboAstraZenecaApproved
43
Rosuvastatin + PlaceboAstraZenecaApproved
35
rosuvastatin + placeboAstraZenecaPhase 1
29
Rosuvastatin + PlaceboAstraZenecaPhase 1
29
Rosuvastatin + AtorvastatinAstraZenecaPhase 3
40
Rosuvastatin + PlaceboAstraZenecaPhase 3
40
Rosuvastatin (5mg,10mg,20mg) + Rosuvastatin 5mgAstraZenecaApproved
39
Vorapaxar + PlaceboMerckPhase 3
40
Vorapaxar + Placebo + Aspirin + ClopidogrelMerckPhase 2
35
Niacin/simvastatin compared to simvastatin alone at 2 dosesMerckApproved
43
lovastatinMerckPhase 2/3
38
Ezetimibe + PlaceboMerckApproved
43
Vorapaxar + PlaceboMerckPhase 3
32
NiaspanMerckPre-clinical
22
MK0633MerckPhase 2
35